Janux Therapeutics (JANX) Receivables - Accured (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Receivables - Accured data on file, last reported at $7.5 million in Q1 2026.

• Receivables - Accured for Q1 2026 came in at $7.5 million, up 33.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (up 33.93% YoY), and the FY2025 annual result was $6.4 million, up 18.52% from the prior year.
• Receivables - Accured advanced to $7.5 million in Q1 2026 per JANX's latest filing, from $6.4 million in the prior quarter.
• Over five years, Receivables - Accured peaked at $7.5 million in Q1 2026 and troughed at $100000.0 in Q1 2022.
• A 5-year average of $3.4 million and a median of $3.9 million in 2024 frame the typical range for Receivables - Accured.
• On a YoY basis, Receivables - Accured climbed as much as 9900.0% in 2022 and fell as far as 98.93% in 2022.
• A 5-year view of Receivables - Accured shows it stood at $700000.0 in 2022, then surged by 214.29% to $2.2 million in 2023, then surged by 145.45% to $5.4 million in 2024, then advanced by 18.52% to $6.4 million in 2025, then advanced by 17.19% to $7.5 million in 2026.
• Business Quant data shows JANX's Receivables - Accured at $7.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.3 million in Q3 2025.